Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol

Arihiko Kanaji, Masaaki Higashi, Masako Namisato, Kenichi Ando, Masato Nakagawa, Yoshiyuki Yato, Hirofusa Ichinose, Toyonori Sakamaki, Harumoto Yamada

研究成果: Article

4 引用 (Scopus)

抄録

There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy. In this study, we report a case of osteoporosis in a man with leprosy, treated by oral administration of risedronate and alfacalcidol. An 82-year-old man with leprosy presented to our hospital with chronic back pain, due to osteoporosis, in July 2002. To prevent the progession of osteoporosis, oral administration of risedronate and alfacalcidol was started for this patient. An increase in forearm BMD and a decrease in the level of urinary crosslinked N-telopeptides of type I collagen (NTx) were observed in January 2003. The patient suffered a trochanteric fracture of the proximal femur at the end of March 2003. Surgical treatment with a sliding-screw plate was performed 5 days after the injury. Complete bony union of the right proximal femur was confirmed by radiography in July 2003. The above findings suggested that the treatment with risedronate and alfacalcidol contributed to the increase in BMD; however, the treatment did not prevent fracture due to osteoporosis in this male patient with leprosy.

元の言語English
ページ(範囲)90-94
ページ数5
ジャーナルJournal of Bone and Mineral Metabolism
23
発行部数1
DOI
出版物ステータスPublished - 01-01-2005

Fingerprint

Hip Fractures
Leprosy
Osteoporosis
Bone Density
Femur
Oral Administration
Therapeutics
Bone Fractures
Back Pain
Collagen Type I
Forearm
Radiography
Chronic Pain
alfacalcidol
Risedronate Sodium
Clinical Trials
Incidence
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

これを引用

Kanaji, Arihiko ; Higashi, Masaaki ; Namisato, Masako ; Ando, Kenichi ; Nakagawa, Masato ; Yato, Yoshiyuki ; Ichinose, Hirofusa ; Sakamaki, Toyonori ; Yamada, Harumoto. / Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol. :: Journal of Bone and Mineral Metabolism. 2005 ; 巻 23, 番号 1. pp. 90-94.
@article{7c105918297c431597871ddd38a660fe,
title = "Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol",
abstract = "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy. In this study, we report a case of osteoporosis in a man with leprosy, treated by oral administration of risedronate and alfacalcidol. An 82-year-old man with leprosy presented to our hospital with chronic back pain, due to osteoporosis, in July 2002. To prevent the progession of osteoporosis, oral administration of risedronate and alfacalcidol was started for this patient. An increase in forearm BMD and a decrease in the level of urinary crosslinked N-telopeptides of type I collagen (NTx) were observed in January 2003. The patient suffered a trochanteric fracture of the proximal femur at the end of March 2003. Surgical treatment with a sliding-screw plate was performed 5 days after the injury. Complete bony union of the right proximal femur was confirmed by radiography in July 2003. The above findings suggested that the treatment with risedronate and alfacalcidol contributed to the increase in BMD; however, the treatment did not prevent fracture due to osteoporosis in this male patient with leprosy.",
author = "Arihiko Kanaji and Masaaki Higashi and Masako Namisato and Kenichi Ando and Masato Nakagawa and Yoshiyuki Yato and Hirofusa Ichinose and Toyonori Sakamaki and Harumoto Yamada",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s00774-004-0546-7",
language = "English",
volume = "23",
pages = "90--94",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "1",

}

Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol. / Kanaji, Arihiko; Higashi, Masaaki; Namisato, Masako; Ando, Kenichi; Nakagawa, Masato; Yato, Yoshiyuki; Ichinose, Hirofusa; Sakamaki, Toyonori; Yamada, Harumoto.

:: Journal of Bone and Mineral Metabolism, 巻 23, 番号 1, 01.01.2005, p. 90-94.

研究成果: Article

TY - JOUR

T1 - Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol

AU - Kanaji, Arihiko

AU - Higashi, Masaaki

AU - Namisato, Masako

AU - Ando, Kenichi

AU - Nakagawa, Masato

AU - Yato, Yoshiyuki

AU - Ichinose, Hirofusa

AU - Sakamaki, Toyonori

AU - Yamada, Harumoto

PY - 2005/1/1

Y1 - 2005/1/1

N2 - There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy. In this study, we report a case of osteoporosis in a man with leprosy, treated by oral administration of risedronate and alfacalcidol. An 82-year-old man with leprosy presented to our hospital with chronic back pain, due to osteoporosis, in July 2002. To prevent the progession of osteoporosis, oral administration of risedronate and alfacalcidol was started for this patient. An increase in forearm BMD and a decrease in the level of urinary crosslinked N-telopeptides of type I collagen (NTx) were observed in January 2003. The patient suffered a trochanteric fracture of the proximal femur at the end of March 2003. Surgical treatment with a sliding-screw plate was performed 5 days after the injury. Complete bony union of the right proximal femur was confirmed by radiography in July 2003. The above findings suggested that the treatment with risedronate and alfacalcidol contributed to the increase in BMD; however, the treatment did not prevent fracture due to osteoporosis in this male patient with leprosy.

AB - There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy. In this study, we report a case of osteoporosis in a man with leprosy, treated by oral administration of risedronate and alfacalcidol. An 82-year-old man with leprosy presented to our hospital with chronic back pain, due to osteoporosis, in July 2002. To prevent the progession of osteoporosis, oral administration of risedronate and alfacalcidol was started for this patient. An increase in forearm BMD and a decrease in the level of urinary crosslinked N-telopeptides of type I collagen (NTx) were observed in January 2003. The patient suffered a trochanteric fracture of the proximal femur at the end of March 2003. Surgical treatment with a sliding-screw plate was performed 5 days after the injury. Complete bony union of the right proximal femur was confirmed by radiography in July 2003. The above findings suggested that the treatment with risedronate and alfacalcidol contributed to the increase in BMD; however, the treatment did not prevent fracture due to osteoporosis in this male patient with leprosy.

UR - http://www.scopus.com/inward/record.url?scp=12444251096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444251096&partnerID=8YFLogxK

U2 - 10.1007/s00774-004-0546-7

DO - 10.1007/s00774-004-0546-7

M3 - Article

C2 - 15616900

AN - SCOPUS:12444251096

VL - 23

SP - 90

EP - 94

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 1

ER -